UNLABELLED: Incorporation coefficients (K*) of arachidonic acid (AA) in the brain are increased in a rat model of neuroinflammation, as are other markers of AA metabolism. Data also indicate that neuroinflammation contributes to Alzheimer's disease (AD). On the basis of these observations, K* for AA was hypothesized to be elevated in patients with AD. METHODS: A total of 8 patients with AD with an average (+/-SD) Mini-Mental State Examination score of 14.7+/-8.4 (mean age, 71.7+/-11.2 y) and 9 controls with a normal Mini-Mental State Examination score (mean age, 68.7+/-5.6 y) were studied. Each subject received a (15)O-water PET scan of regional cerebral blood flow, followed after 15 min by a 1-(11)C-AA scan of regional K* for AA. RESULTS: In the patients with AD, compared with control subjects, global gray matter K* for AA (corrected or uncorrected for the partial-volume error [PVE]) was significantly elevated, whereas only PVE-uncorrected global cerebral blood flow was reduced significantly (P<0.05). A false-discovery-rate procedure indicated that PVE-corrected K* for AA was increased in 78 of 90 identified hemispheric gray matter regions. PVE-corrected regional cerebral blood flow, although decreased in 12 regions at P<0.01 by an unpaired t test, did not survive the false-discovery-rate procedure. The surviving K* increments were widespread in the neocortex but were absent in caudate, pallidum, and thalamic regions. CONCLUSION: These preliminary results show that K* for AA is widely elevated in the AD brain, particularly in regions reported to have high densities of senile (neuritic) plaques with activated microglia. To the extent that the elevations represent upregulated AA metabolism associated with neuroinflammation, PET with 1-(11)C-AA could be used to examine neuroinflammation in patients with AD and other brain diseases.
UNLABELLED: Incorporation coefficients (K*) of arachidonic acid (AA) in the brain are increased in a rat model of neuroinflammation, as are other markers of AA metabolism. Data also indicate that neuroinflammation contributes to Alzheimer's disease (AD). On the basis of these observations, K* for AA was hypothesized to be elevated in patients with AD. METHODS: A total of 8 patients with AD with an average (+/-SD) Mini-Mental State Examination score of 14.7+/-8.4 (mean age, 71.7+/-11.2 y) and 9 controls with a normal Mini-Mental State Examination score (mean age, 68.7+/-5.6 y) were studied. Each subject received a (15)O-water PET scan of regional cerebral blood flow, followed after 15 min by a 1-(11)C-AA scan of regional K* for AA. RESULTS: In the patients with AD, compared with control subjects, global gray matter K* for AA (corrected or uncorrected for the partial-volume error [PVE]) was significantly elevated, whereas only PVE-uncorrected global cerebral blood flow was reduced significantly (P<0.05). A false-discovery-rate procedure indicated that PVE-corrected K* for AA was increased in 78 of 90 identified hemispheric gray matter regions. PVE-corrected regional cerebral blood flow, although decreased in 12 regions at P<0.01 by an unpaired t test, did not survive the false-discovery-rate procedure. The surviving K* increments were widespread in the neocortex but were absent in caudate, pallidum, and thalamic regions. CONCLUSION: These preliminary results show that K* for AA is widely elevated in the AD brain, particularly in regions reported to have high densities of senile (neuritic) plaques with activated microglia. To the extent that the elevations represent upregulated AA metabolism associated with neuroinflammation, PET with 1-(11)C-AA could be used to examine neuroinflammation in patients with AD and other brain diseases.
Authors: N M Kemppainen; S Aalto; I A Wilson; K Någren; S Helin; A Brück; V Oikonen; M Kailajärvi; M Scheinin; M Viitanen; R Parkkola; J O Rinne Journal: Neurology Date: 2006-09-13 Impact factor: 9.910
Authors: J T Greenamyre; W F Maragos; R L Albin; J B Penney; A B Young Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 1988 Impact factor: 5.067
Authors: Giuseppe Esposito; Giampiero Giovacchini; Margaret Der; Jeih-San Liow; Abesh K Bhattacharjee; Kaizong Ma; Peter Herscovitch; Michael Channing; William C Eckelman; Mark Hallett; Richard E Carson; Stanley I Rapoport Journal: Neuroimage Date: 2006-12-29 Impact factor: 6.556
Authors: James C DeMar; Ho-Joo Lee; Kaizong Ma; Lisa Chang; Jane M Bell; Stanley I Rapoport; Richard P Bazinet Journal: Biochim Biophys Acta Date: 2006-07-08
Authors: Mireille Basselin; Nelly E Villacreses; Ho-Joo Lee; Jane M Bell; Stanley I Rapoport Journal: J Neurochem Date: 2007-05-04 Impact factor: 5.372
Authors: Madhav Thambisetty; Kathy A Gallardo; Jeih-San Liow; Lori L Beason-Held; John C Umhau; Abesh K Bhattacharjee; Margaret Der; Peter Herscovitch; Judith L Rapoport; Stanley I Rapoport Journal: J Cereb Blood Flow Metab Date: 2011-12-14 Impact factor: 6.200
Authors: Abesh Kumar Bhattacharjee; Laura White; Lisa Chang; Kaizong Ma; G Jean Harry; Joseph Deutsch; Stanley I Rapoport Journal: Neurochem Res Date: 2012-03-16 Impact factor: 3.996
Authors: Mireille Basselin; Meredith A Fox; Lisa Chang; Jane M Bell; Dede Greenstein; Mei Chen; Dennis L Murphy; Stanley I Rapoport Journal: Neuropsychopharmacology Date: 2009-01-14 Impact factor: 7.853